

REMARKS

Claims 1-13 and 18-23 were pending in the present application prior to this amendment, with claims 18 and 23 having been withdrawn. In light of the amendments made herein, claims 12 and 13 remain pending. Further consideration of these claims is hereby requested.

Without prejudice to the Applicants' right to file further continuation and/or divisional applications directed to any subject matter having basis in the specification, whether or not cancelled from the claims during prosecution, Applicants have limited the claims of the present application to a single compound, salts thereof, and pharmaceutical compositions of the compound or salt thereof. Claims 12 and 13 have been amended to this end. The remaining claims have been cancelled.

The rejection under 35 USC §112 of claims 11 is rendered moot in light of the cancellation of that claim. The rejections under §103 and double patenting are also rendered moot in light of the amendments made to claims.

CONCLUSION

Applicants believe that in light of the amendments made herein, the rejections and objections made in the prior action are moot, and that the claims are in a condition for allowance. Favorable consideration and issuance of a Notice of Allowance is respectfully requested.

Should the Examiner have any questions or wish to discuss any aspect of this case, the Examiner is encouraged to call the undersigned at the number below. If any additional fees or charges are required by this paper, the Commissioner is hereby authorized to charge Deposit Account No. 07-1392 accordingly.

Respectfully submitted,

/James P. Riek/

James P. Riek
Attorney for Applicant
Reg. No. 39,009

Date: 15 December 2010
Customer No. 23347
GlaxoSmithKline
Global Patents
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8022
Facsimile: (919) 483-7988